Breaking News, Trials & Filings

Trials & Filings in Brief: Oct. 10, 2013

Alkermes, Chelsea, CirrusGalectin, Gilead, Lundbeck, Otsuka, Medivir, Pergamum and Relyspa

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Preclinical Galectin posts fibrosis . . . read more Medivir selects neuropathic pain candidate . . . read more Phase II Pergamum peptide posts positive results . . . read more Phase III Gilead Cuts CLL Study Short After Positive Results  . . . read more Lundbeck, Otsuka start Alzheimer’s trials . . . read more Relypsa posts positive results for patiromer . . . read more Filings Alkermes MDD drug gets fast-track status . . . read more Chelsea NOH treatment to get advisory review . . ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters